Abstract

COVID-19 (coronavirus disease-19) involves humans as well as animals and may cause serious damage to the respiratory tract including the lung. This pathogenic virus has been identified in swabs performed on the throat and nose of patients who suffer from or are suspected of the disease. When COVID-19 infect the upper and lower respiratory tract it can cause mild or highly acute respiratory syndrome with consequent release of pro-inflammatory cytokines, including interleukin (IL)-1b and IL-6. The binding of COVID-19 to the Toll Like Receptor (TLR) causes the release of pro-IL-1b which is cleaved by caspase-1, followed by inflammasome activation and production of active mature IL-1b which is a mediator of lung inflammation, fever and fibrosis. Suppression of pro-inflammatory IL-1 family members and IL-6 have been shown to have a therapeutic effect in many inflammatory diseases, including viral infections. Cytokine IL-37 has the ability to suppress innate and acquired immune response and also has the capacity to inhibit inflammation by acting on IL-18Ra receptor. IL-37 performs its immunosuppressive activity by acting on mTOR and increasing the adenosine monophosphate (AMP) kinase. This cytokine inhibits class II histocompatibility complex (MHC) molecules and inflammation in inflammatory diseases by suppressing MyD88 and subsequently IL-1β, IL-6, TNF and CCL2. The suppression of IL-1b by IL-37 in inflammatory state induced by COVID-19 can have a new therapeutic effect previously unknown. Another inhibitory cytokine is IL-38, the newest cytokine of the IL-1 family members, produced by several immune cells including B cells and macrophages. IL-38 is also a suppressor cytokine which inhibits IL-1b and other pro-inflammatory IL-family members. IL-38 is a potential therapeutic cytokine which inhibits inflammation in viral infections including that caused by COVID-19, providing a new relevant strategy.

Keywords

InflammationCoronavirus disease 2019 (COVID-19)ImmunologyMedicineInflammatory responseProinflammatory cytokineInterleukinLungCytokinePathologyInternal medicineInfectious disease (medical specialty)Disease

Affiliated Institutions

Related Publications

Publication Info

Year
2020
Type
article
Volume
34
Issue
2
Pages
1-1
Citations
1246
Access
Closed

External Links

Social Impact

Social media, news, blog, policy document mentions

Citation Metrics

1246
OpenAlex

Cite This

Pio Conti, Gianpaolo Ronconi, A. Caraffa et al. (2020). Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by COVID-19: anti-inflammatory strategies.. Journal of Biological Regulators and Homeostatic Agents/Journal of Biological Regulators & Homeostatic Agents , 34 (2) , 1-1. https://doi.org/10.23812/conti-e

Identifiers

DOI
10.23812/conti-e